Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nitrosourea

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28 result(s) found for: Nitrosourea. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-005548-25 Sponsor Protocol Number: RNOP-12 Start Date*: 2008-07-28
    Sponsor Name:Freistaat Bayern, vertreten durch Klinikum der Universität Regensburg
    Full Title: Prospective, randomised (using minimisation), double-blind, placebo controlled study to evaluate the safety and efficacy of human normal immunoglobulin as a prophylactic agent against infections in...
    Medical condition: Patients with high-grade gliomas (world health organisation [WHO] grade III or IV) in the first relapse after first-line therapy including chemotherapy with or without nitrososurea, with a life exp...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004063-29 Sponsor Protocol Number: CSTI571BDE40 Start Date*: 2004-12-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Glivec (imatinib mesylate) in combination with hydroxyurea or hydroxyurea alone as an oral therapy in temozolomide resistant progressive glioblastoma patients
    Medical condition: Glioblastoma multiforme/astrocytoma WHO grade IV, with progression on temozolomide containing regimen
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002600-41 Sponsor Protocol Number: CSTI571H2201 Start Date*: 2006-01-17
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Estudio fase II, abierto, multicéntrico, no comparativo, que evalúa la eficacia de Glivec® con Hidroxiurea en pacientes con Glioblastoma Multiforme (GBM) en progresión, que no reciben fármacos anti...
    Medical condition: Glioblastoma multiforme progresivo (GBM) tras fallo a terapia de primera línea definida por cirugía, radioterapia y exposición a un régimen de quimioterapia de Temozolamida (TMZ).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) SE (Completed) DE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002603-16 Sponsor Protocol Number: CSTI571H2202 Start Date*: 2006-01-17
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Estudio fase II, abierto, multicéntrico, no comparativo, que evalúa la eficacia de Glivec® con Hidroxiurea en pacientes con Glioblastoma Multiforme (GBM) en progresión, que reciben fármacos anticon...
    Medical condition: Glioblastoma multiforme progresivo (GBM) tras fallo a terapia de primera línea definida por cirugía, radioterapia y exposición a un régimen de quimioterapia de Temozolamida (TMZ).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) SE (Completed) DE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019356-50 Sponsor Protocol Number: NIBIT-M1 Start Date*: 2010-04-27
    Sponsor Name:NIBIT (NETWORK ITALIANO PER LA BIO-IMMUNOTERAPIA DEI TUMORI)
    Full Title: A Phase II Study of the Combination of Ipilimumab and Fotemustine in Patients with Unresectable Locally Advanced or Metastatic Malignant Melanoma
    Medical condition: Patients with Unresectable Locally Advanced or Metastatic Malignant Melanoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025670 LLT
    9.1 10025671 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011498-34 Sponsor Protocol Number: TAS 2009 Start Date*: 2009-10-22
    Sponsor Name:Ergomed Clinical Research Limited
    Full Title: An Open-Label, Multi-Center Phase I/II Dose Escalation Study to Investigate the Safety and Tolerability of Multiple Doses of Oral Tasidotin HCL in Patients with Advanced Solid Tumors (part A), and ...
    Medical condition: Solid tumours and metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065143 Malignant solid tumour LLT
    9.1 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021639-15 Sponsor Protocol Number: GC1008 Start Date*: 2011-07-07
    Sponsor Name:University Medical Center Groningen
    Full Title: Guiding GC1008 treatment of primary brain tumors by 89Zr-GC1008 PET imaging.
    Medical condition: High grade malignant glioma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012186-63 Sponsor Protocol Number: LWNO 0901 Start Date*: 2009-11-05
    Sponsor Name:Erasmus MC, more specifically for and on behalf of the department of Neurology/Neuro-Oncology
    Full Title: Landelijke Werkgroep voor Neuro-Oncologie trial (LWNO 0901) Randomized phase II study of Bevacizumab versus Bevacizumab plus Lomustine in patients with recurrent Glioblastoma: the BELOB trial
    Medical condition: Patients with recurrent glioblastoma multiforme who failed combined chemo-irradiation with temozolomide.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10018336 Glioblastoma LLT
    12.0 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001282-17 Sponsor Protocol Number: E7389-G000-223 Start Date*: 2018-03-23
    Sponsor Name:Eisai Inc.
    Full Title: A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma S...
    Medical condition: Relapsed/Refractory Rhabdomyosarcoma Non-rhabdomyosarcoma Soft Tissue Sarcoma Ewing Sarcoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-004137-18 Sponsor Protocol Number: CO-ACT-001 Start Date*: 2007-10-19
    Sponsor Name:Collaborative group for Adrenocortical Carcinoma Therapy (COAT) [...]
    1. Collaborative group for Adrenocortical Carcinoma Therapy (COAT)
    2. University of Würzburg, Internat. study-Coordinator
    Full Title: First International Randomized trial in locally advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)
    Medical condition: chemotherapy with etoposide, doxorubicin and cisplatin plus mitotane (EDP/M) as first line treatment versus streptozotocin plus mitotane (Sz/M) as first line treatment in advanced and Metastatic Ad...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10001388 Adrenocortical carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2019-001238-32 Sponsor Protocol Number: ADVL1622 Start Date*: 2019-09-26
    Sponsor Name:National Cancer Institute Cancer Therapy Evaluation
    Full Title: Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
    Medical condition: Ewing sarcoma, Rhabdomyosarcoma, Non rhabdomyosarcoma, Wilms Tumor, Osteosarcoma and Other Rare Tumors
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-023135-42 Sponsor Protocol Number: VIT-0910 Start Date*: 2016-07-05
    Sponsor Name:Centre Oscar Lambret
    Full Title: INTERNATIONAL RANDOMIZED PHASE II TRIAL OF THE COMBINATION OF VINCRISTINE AND IRINOTECAN WITH OR WITHOUT TEMOZOLOMIDE (VI OR VIT) IN CHILDREN AND ADULTS WITH REFRACTORY OR RELAPSED RHABDOMYOSARCOMA
    Medical condition: Recurrent or refractory rhabdomyosarcoma
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039027 Rhabdomyosarcoma recurrent PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) NL (Ongoing) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-001971-30 Sponsor Protocol Number: AP23573-08-207 Start Date*: 2008-11-10
    Sponsor Name:Merck & Co, Inc.
    Full Title: A Phase II Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination with Trastuzumab for Patients with HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer
    Medical condition: HER2-positive metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-001306-20 Sponsor Protocol Number: ADVL0815 Start Date*: 2012-03-08
    Sponsor Name:The National Cancer Institute (NCI)
    Full Title: A PHASE I STUDY OF PAZOPANIB AS A SINGLE AGENT FOR CHILDREN WITH RELAPSED OR REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS
    Medical condition: Refractory solid tumors
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065143 Malignant solid tumour LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-003468-19 Sponsor Protocol Number: ADVL0912 Start Date*: 2020-08-14
    Sponsor Name:Children’s Oncology Group
    Full Title: ADVL0912: A PHASE 1/2 STUDY OF PF02341066, AN ORAL SMALL MOLECULE INHIBITOR OF ANAPLASTIC LYMPHOMA KINASE (ALK) AND C-MET, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID TUMORS AND ANAPLASTIC LARGE CEL...
    Medical condition: malignant solid tumors including Inflammatory myofibroblastic tumor (IMT) and anaplastic large-cell lymphoma (ALCL)
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-001921-25 Sponsor Protocol Number: CA163115 Start Date*: 2006-12-19
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as first Line Therapy for Locally Recurrent or Metastatic Breast Cancer.
    Medical condition: Locally Recurrent or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003005-10 Sponsor Protocol Number: IGR2012/1883 Start Date*: 2013-06-06
    Sponsor Name:Gustave Roussy
    Full Title: PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA
    Medical condition: Children, adolescents and young adults with refractory or recurrent low-grade gliomas, and children, adolescents and young adults with neurofibromatosis type 1 and previously untreated low-grade g...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038111 Recurrent cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070308 Refractory cancer PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed) FR (Ongoing) NL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001083-38 Sponsor Protocol Number: GISG-15 Start Date*: 2018-03-14
    Sponsor Name:Universitätsmedizin Greifswald
    Full Title: Combined treatment with Nivolumab and Trabectedin in patients with metastatic or inoperable soft tissue Sarcomas - The NiTraSarc Phase II Trial
    Medical condition: metastatic or inoperable soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024191 Leiomyosarcoma metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024194 Leiomyosarcoma recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024629 Liposarcoma metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024632 Liposarcoma recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068595 Sarcoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003736-77 Sponsor Protocol Number: E7080-A001-216 Start Date*: 2023-03-28
    Sponsor Name:Eisai Inc.
    Full Title: A Phase 1/2 Study of Lenvatinib in Combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
    Medical condition: Recurrent and Refractory Solid Tumors
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-000686-37 Sponsor Protocol Number: PR-20-5006-C Start Date*: 2013-09-11
    Sponsor Name:Tesaro, Inc.
    Full Title: A Phase 1/2a, Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients with Advanced Solid Tumors and Lymphomas
    Medical condition: Solid tumors or lymphomas that have failed standard therapies or for which no standard treatment option(s) exist.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10065147 Malignant solid tumor LLT
    19.0 100000004851 10025324 Lymphomas unspecified NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) PL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 07:35:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA